Skip to main content
SpringerLink
Log in

What Triggers the Initiative of Developments in Transfusion Medicine: Advances in Ex Vivo Haematopoietic Cell Therapy and Next Generation Transfusion Products

  • Chapter
Trigger Factors in Transfusion Medicine

Part of the book series: Developments in Hematology and Immunology ((DIHI,volume 31))

  • 37 Accesses

Abstract

Transfusion medicine and blood banking have evolved over the years from the collection and use of whole blood to the fractionation of blood into plasma and cell components including red blood cells, platelets and granulocytes (Figure 1). Plasma has been further refined and fractionated into specific components of significant therapeutic value including albumin, immunoglobulin and coagulation components such as Factor VIII. The evolution of molecular biology and recombinant protein technology has had a significant impact on the field and resulted in ways to generate therapeutic proteins which are functionally equivalent to proteins derived directly from the plasma. The best example of this is Factor VIII for the treatment of haemophilia. The therapeutic form of the protein has moved from being a plasma fraction to affinity purified Factor VIII using monoclonal antibody technology to the recombinant form of this protein which was introduced commercially in 1993. Many other basic plasma proteins have now been cloned and it is anticipated that many of these will be produced cost-effectively and applied clinically. It can also be anticipated that there will be a need for specific antibody therapy for infectious disease, autoimmune disease, transplantation, and cancer therapy. Such antibodies may augment or even replace the use of immunoglobulin fractions from plasma in situations where broad spectrum activity is not required.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Farese AM, Hunt P, Boone T, MacVittie TJ. Recombinant human megakaryocyte growth and development factor stimulates thrombocytopoiesis in normal primates. Blood 1995;86:54–9.

    PubMed  CAS  Google Scholar 

  2. Lok SI, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombo-poietin cDNA and stimulation of platelet production in vivo. Nature 1995;369:565–68.

    Article  Google Scholar 

  3. De Sauvage FJ, Hass PE, Spencer SD, et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature 1994;369:533–38.

    Article  PubMed  Google Scholar 

  4. Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994;369:568–70.

    Article  PubMed  CAS  Google Scholar 

  5. Ho AD, Gluck S, Germond C, et al. Optimal timing for collections of blood progenitor cells following induction chemotherapy and granulocyte-macrophage colony-stimulating factor for autologous transplantation in advanced breast cancer. Leukemia 1993;7:1738–46.

    PubMed  CAS  Google Scholar 

  6. Bender JG, To LB, Williams S, Schwartzberg LS. Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1992;1:329–41.

    Article  PubMed  CAS  Google Scholar 

  7. Dreger P, Marquardt P, Haferlach T, et al. Effective mobilisation of peripheral blood progenitor cells with ‘Dexa-BEAM’ and G-CSF: Timing of harvesting and composition of the leukapheresis product. Br J Cancer 1993;68:950–57.

    Article  PubMed  CAS  Google Scholar 

  8. Uyl-de Groot CA, Ossenkoppele GJ, van Riet AAPM, Rutten FFH. The costs of peripheral blood progenitor cell reinfusion mobilised by granulocyte colony-stimulating factor following high dose melphalan as compared with conventional therapy in multiple myeloma. Eur J Cancer 1994;30A:457–59.

    Article  PubMed  CAS  Google Scholar 

  9. Faucher C, le Corroller AG, Blaise D, et al. Comparison of G-CSF-primed peripheral blood progenitor cells and bone marrow auto transplantation: Clinical assessment and cost-effectiveness. Bone Marrow Transplant 1994;14:895–901.

    PubMed  CAS  Google Scholar 

  10. Körbling M, Przepiorka D, Huh YO, et al. Allogeneic blood stem cell transplantation for refractory leukemia and lymphoma: Potential advantage of blood over marrow allografts. Blood 1995;85:1659–65.

    PubMed  Google Scholar 

  11. Bensinger WI, Weaver CH, Appelbaum FR, et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony-stimulating factor. Blood 1995;85:1655–58.

    PubMed  CAS  Google Scholar 

  12. Schmitz N, Dreger P, Suttorp M, et al. Primary transplantation of allogeneic peripheral blood progenitor cells mobilized by filgrastim (granulocyte colony-stimulating factor). Blood 1995;85:1666–72.

    PubMed  CAS  Google Scholar 

  13. Kessler DA, Siegel JP, Noguchi PD, Zoon KC, Feiden KL, Woodcock J. Regulation of somatic-cell therapy and gene therapy by the food and drug administration. N Engl J Med 1993;329:1169–73.

    Article  PubMed  CAS  Google Scholar 

  14. Williams SF, Bender JG, Zimmerman T, et al. Selection and expansion of CD34 cells: Their clinical utility for the treatment of cytopenias. Bone Marrow Transplant 1995;15(Suppl 2):S41 [Abstract].

    Google Scholar 

  15. Brugger W, Heimfeld S, Berenson RJ, Mertelsmann R, Kanz L. Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. N Engl J Med 1995;333:283–87.

    Article  PubMed  Google Scholar 

  16. Koller MR, Bender JG, Miller WM, Papoutsakis ET. Expansion of primitive human hematopoietic progenitors in a perfusion bioreactor system with IL-3, IL-6, and stem cell factor. Bio/Technology 1993;11:358–63.

    Article  PubMed  CAS  Google Scholar 

  17. Zimmerman T, Williams SF, Bender JG, et al. Clinical use of selected and expanded peripheral blood CD34+ cells: A preliminary report of feasibility and safety. J Hematother 1995;4:527–29.

    Article  PubMed  CAS  Google Scholar 

  18. Bender JG, Zimmerman T, Lee WJ, et al. Large scale selection of CD34+ cells and expansion of neutrophil precursors in PIXY321 for clinical application. Blood 1994;84: 542a[Abstract].

    Google Scholar 

  19. O’Shaughnessy JA, Cowan KH, Nienhuis AW, et al. Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer. Hum Gene Ther 1994;5:891–911.

    Article  PubMed  Google Scholar 

  20. Simpson S J, Vachula M, Kennedy MJ, et al. Detection of tumor cells in the bone marrow, peripheral blood, and apheresis products of breast cancer patients using flow cytometry. Exp Hematol 1995;23:1062–68.

    PubMed  CAS  Google Scholar 

  21. Brenner MK, Rill DR, Moen RC, et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993;341:85–6.

    Article  PubMed  CAS  Google Scholar 

  22. Shpall EJ, Bast RC, Joines WT, et al. Immunomagnetic purging of breast cancer from bone marrow for autologous transplantation. Bone Marrow Transplant 1991;7:145–51.

    PubMed  CAS  Google Scholar 

  23. Brugger W, Bross KJ, Glatt M, Weber F, Mertelsmann R, Kanz L. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994;83:636–40.

    PubMed  CAS  Google Scholar 

  24. Moss TJ, Sanders DG, Lasky LC, Bostrom B. Contamination of peripheral blood stem cell harvests by circulating neuroblastoma cells. Blood 1990;76:1879–83.

    PubMed  CAS  Google Scholar 

  25. Craig JIO, Langlands K, Parker AC, Antony RS. Molecular detection of tumor contamination in peripheral blood stem cell harvests. Exp Hematol 1994;22:898–902.

    PubMed  CAS  Google Scholar 

  26. Gribben JG, Freedman AS, Neuberg D, et al. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. N Engl J Med 1991;325:1525–33.

    Article  PubMed  CAS  Google Scholar 

  27. Butturini A, Gale RP. Clinical trials of T-cell depletion: Current controversies, future directions. Bone Marrow Transplant 1989:495–509.

    Google Scholar 

  28. Kolb H, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990;76:2462–65.

    PubMed  CAS  Google Scholar 

  29. Frassoni F, Fagioli F, Sessarego M, et al. The effect of donor leucocyte infusion in patients with leukemia following allogeneic bone marrow transplantation. Exp Hematol 1992;20:712a[Abstract].

    Google Scholar 

  30. Porter D, Roth M, McGarigle C, Ferrara J, Antin J. Induction of graft-versus-host disease as immunotherapy for relapsed chronic myeloid leukemia. N Engl J Med 1994;330:100–6.

    Article  PubMed  CAS  Google Scholar 

  31. Traycoff CM, Broun ER, Burgess J, et al. Evaluation of the hematopoietic potential of CD34 enriched autologous bone marrow grafts prepared with the Baxter Isolex 300. Exp Hematol 1994;22:824[Abstract].

    Google Scholar 

  32. Straka C, Drexler E, Mitterer M, et al. Autotransplantation of B-cell purged peripheral blood progenitor cells in B-cell lymphoma. Lancet 1995;345:797–98.

    Article  PubMed  CAS  Google Scholar 

  33. Dreger P, von Neuhoff N, Suttorp M, Loftier H, Schmitz N. Rapid engraftment of peripheral blood progenitor cell grafts purged with B cell-specific monoclonal antibodies and immunomagnetic beads. Bone Marrow Transplant 1995;16:627–29.

    PubMed  CAS  Google Scholar 

  34. Kvalheim G, Jakobsen E, Holte H, et al. Autologous bone marrow transplantation of non-Hodgkin’s lymphoma patients with marrow purged using immunomagnetic beads. Adv Bone Marrow Purging/Processing: Fourth Intl Symp 1994:133–38.

    Google Scholar 

  35. Wodinsky HB, Dillman RO, MacDonald SA. Assessing peripheral blood stem cell transplant technology. J Oncol Manage 1994:22–7.

    Google Scholar 

  36. Smith SL, Bender JG, Maples PB, et al. Expansion of neutrophil precursors and progenitors in suspension cultures of CD34 cells enriched from human bone marrow. Exp Hematol 1993;21:870–77.

    PubMed  CAS  Google Scholar 

  37. Haylock DN, To LB, Dowse TL, Juttner CA, Simmons PJ. Ex vivo expansion and maturation of peripheral blood CD34 cells into the myeloid lineage. Blood 1992; 80:1405–12.

    PubMed  CAS  Google Scholar 

  38. McCullough J, Clay ME, Fautsch S, et al. Proposed policies and procedures for the establishment of a cord blood bank. Blood Cells 1994;20:609–26.

    PubMed  CAS  Google Scholar 

  39. Rubinstein P, Rosenfield RE, Adamson JW, Stevens CE. Stored placental blood for unrelated bone marrow reconstitution. Blood 1993;81:1679–90.

    PubMed  CAS  Google Scholar 

  40. Gluckman E, Broxmeyer HE, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fanconi’s anemia by means of umbilical cord blood from an HLA-identical sibling. N Engl J Med 1989;321:1174–78.

    Article  PubMed  CAS  Google Scholar 

  41. Wagner JE, Broxmeyer HE, Byrd RL, et al. Transplantation of umbilical cord blood after myeloablative therapy: Analysis of engraftment. Blood 1992;79:1874–81.

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. D. E. van Epps
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Red Cross Blood Bank Noord-Nederland, The Netherlands

    C. Th. Smit Sibinga  & P. C. Das  & 

  2. Yale New Haven Hospital Blood Bank, New Haven, CT, USA

    E. L. Snyder (chairmain) (chairmain)

Rights and permissions

Reprints and permissions

Copyright information

© 1996 Kluwer Academic Publishers

About this chapter

Cite this chapter

van Epps, D.E. (1996). What Triggers the Initiative of Developments in Transfusion Medicine: Advances in Ex Vivo Haematopoietic Cell Therapy and Next Generation Transfusion Products. In: Sibinga, C.T.S., Das, P.C., Snyder, E.L. (eds) Trigger Factors in Transfusion Medicine. Developments in Hematology and Immunology, vol 31. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1287-1_16

Download citation

  • DOI: https://doi.org/10.1007/978-1-4613-1287-1_16

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4612-8550-2

  • Online ISBN: 978-1-4613-1287-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation